In 2023, the U.S. Food and Drug Administration (FDA) approved one respiratory syncytial virus (RSV) vaccine and an updated monoclonal antibody therapy to prevent respiratory disease in very young children.
Given these were new options, health officials did not know which product pregnant women would prefer during the 2023-2024 RSV season.
Pregnant Women Prefer RSV Passive Immunization Protection for Infants
Meds Rarely Offered for COVID-19 Patients at High Risk for Progression
No reason other than mild symptoms given for almost half of patients at high risk for progression who were not offered treatment